Bibliographic information
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Maintained
Monitoring patient response to MDR/RR-TB treatment using culture : In multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens, the performance of sputum culture in addition to sputum smear microscopy is recommended to monitor treatment response. It is desirable for sputum culture to be repeated at monthly intervals.
Recommended in favor
Strong
Certainty of evidence
Moderate
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO consolidated guidelines on drug-resistant tuberculosis treatment
Year2019
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment
Year2020
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWHO